Improving Anticancer Activity of Chrysin using Tumor Microenvironment pH-Responsive and Self-Assembled Nanoparticles

Area of Science:

• Biomaterials Science
• Nanotechnology
• Pharmacology

Background:

• Chrysin, a natural compound, shows therapeutic potential but suffers from poor physicochemical properties.
• Poor solubility and bioavailability limit the clinical application of native chrysin.
• Nanoparticle formulations are explored to enhance drug delivery and efficacy.

Purpose of the Study:

• To develop poly(ethylene) glycol (PEG)-conjugated chrysin nanoparticles (PCNPs) for improved cancer therapy.
• To investigate tumor microenvironment-specific drug release using different linkers.
• To evaluate the anticancer efficacy of PCNPs against human breast cancer cells.

Main Methods:

• PEGylated chrysin nanoparticles (PCNP-1 and PCNP-2) were synthesized using succinoyl and cis-aconityl linkers, respectively.
• Nanoparticle characterization included DLS, TEM, XRD, and DSC analyses.
• In vitro anticancer activity was assessed via drug release studies, apoptosis assays, and colony formation inhibition assays.

Main Results:

• Both PCNP-1 and PCNP-2 were successfully synthesized and characterized.
• PCNP-2 exhibited superior drug release kinetics and enhanced anticancer activity compared to native chrysin and PCNP-1.
• PCNP-2 significantly induced apoptosis and inhibited the proliferation of human breast cancer cells.

Conclusions:

• PEGylation of chrysin via cis-aconityl linker (PCNP-2) effectively improves its therapeutic properties.
• PCNPs offer a promising approach to overcome the limitations of native chrysin for cancer treatment.
• This nanoparticle-based drug delivery system represents a potential advancement in breast cancer therapy.